09:48pm Sunday 17 December 2017

Misuse of FDA Exemption Law May Harm Vulnerable Psychiatric Patients

NEW YORK – Warning that patients could be at risk, an interdisciplinary group of multinational investigators is calling on the U.S. Congress and federal regulators to tighten a law that permits use of brain devices to treat rare neuropsychiatric disorders without supporting clinical trials or stringent patient oversight.

In the February issue of the journal Health Affairs, published today, lead author and Weill Cornell Medical College ethicist Dr. Joseph J. Fins says that the FDA’s Humanitarian Device Exemption (HDE) regulation should be revised so that uses of such devices in neuropsychiatric patients meet the highest standards of clinical research, patient safety and research integrity.

The authors voice concern that the humanitarian approval allows device manufacturers to seek a “simpler, cheaper and faster approval process” while depriving patients of “the rigorous trial that the severity and complexity of their condition warrants, as well as hampering scientific discovery.”

They make the case for revision by examining how the law was used to approve deep brain stimulation (DBS) in patients with treatment-resistant obsessive-compulsive disorder (OCD), which they argue is not a rare disorder. The researchers say such misuse of the law could open the door to a number of other inappropriate applications of what was intended to be compassionate legislation designed for orphan disorders that affect only a few thousand Americans a year.

“We believe there needs to be more careful regulation of the use of the Humanitarian Device Exemption in psychiatric patients,” says Dr. Fins, the E. William Davis Jr., M.D. Professor of Medical Ethics, chief of the Division of Medical Ethics and professor of medicine, professor of public health and professor of medicine in psychiatry at Weill Cornell Medical College.

“We want to ensure that only orphan diseases are included in this exemption and that safety information is collected from every patient treated with these devices,” adds Dr. Fins, who also serves as director of medical ethics at NewYork-Presbyterian Hospital/Weill Cornell Medical Center and chairs its ethics committee.

“Stimulating various areas of the brain in different ways to treat a variety of disorders could produce a wide array of effects, but under the Humanitarian Device Exemption, there is no requirement for clinicians to obtain efficacy data or systematically collect information on adverse events or even to ensure that patients are protected to the fullest extent possible,” he says. “That has to change.”

The commentary’s contributing authors, from the U.S. and Europe, have expertise in psychiatry, neurosurgery, neuropsychology, philosophy, ethics and the law.

Congress established the humanitarian device exemption in the Safe Medical Devices Act of 1990. The law sought to help bring novel devices to the market to treat uncommon conditions that otherwise might not attract the attention of device manufacturers. The act required that in order to receive such an exemption, the device must be intended to diagnose or treat conditions that affect 4,000 or fewer people in the U.S. annually.

Devices considered under this exemption are not subjected to the rigorous study required of other devices intended for use in common disorders. Those devices undergo an Investigational Device Exemption (IDE) review, which subjects the device to clinical trials that gauge both safety and effectiveness. A clinician’s use of an IDE has to be approved by the institutional review board (IRB), and further requires informed consent from all patients and clear labeling that the device is considered investigational.

If the FDA’s Center for Devices and Radiological Health approves a humanitarian device exemption, as requested by a manufacturer, that device can be marketed without evidence of effectiveness. Clinicians go through their local IRB for approval to use the device, but patients do not sign a research informed consent document and may not clearly understand that the device to be used has not been evaluated for clinical benefit, the authors say. This can confuse patients and foster a therapeutic misconception about an experimental intervention, especially when device manufacturers market the device as a new therapy. Furthermore, studies are never conducted to clarify how the mechanism of action works, which the authors believe is a lost scientific opportunity for discovery.

Specific Recommendations

The authors are not advocating for elimination of the humanitarian device exemption but are calling for more careful regulation of its use in psychiatric research so that critical safety information is not side-stepped.

They suggest that in approving such future applications, the FDA should make sure the disorder in question is indeed rare. But they also suggest that device manufacturers be required to collect safety data and place it in a central repository, as well as develop a plan to monitor safety data similar to what is required in an IDE application. Finally, to protect patients, they suggest IRBs enlist the assistance of advocates who can help ensure patients are competent enough to provide informed consent, understanding that the clinical benefit of the device has not been proven.

“Currently the safety and efficacy data collected from researchers who obtain a humanitarian device exemption remains in a silo — no one else sees it,” says Dr. Fins. “Requiring clinicians to compile data into a central repository can highlight unexpected side effects as well as benefits and possible other uses. This is the least we can do for our patients.”

The authors are part of a research group called Deep Brain Stimulation in Psychiatry: Guidance for Responsible Research and Application, which is funded by an unrestricted grant from the Volkswagen Foundation to Europäische Akademie GmbH (Bad Neuenahr-Ahrweiler, Germany) and the Department of Psychiatry of the University of Bonn. Some of the authors have disclosed potential conflicts of interest in the study manuscript.

In addition to Dr. Fins, the authors include: Dr. Helen Mayberg, from Emory University; Dr. Bart Nuttin, at the University Hospitals in Leuven, Belgium; Dr. Cynthia S. Kubu, from the Cleveland Clinic; Dr. Thorsten Galert, from Europäische Akademie GmbH; Dr. Volker Sturm, at the Neuroscience Institute Hanover, in Cologne, Germany; Katja Stoppenbrink, at the University of Luxembourg; Dr. Reinhard Merkel, at the University of Hamburg, in Germany; and senior author, Dr. Thomas Schlaepfer, at the University of Bonn in Germany.

Disclosure: The Weill Cornell Medical College Institutional Review Board has approved the use of deep brain stimulation for obsessive-compulsive disorder under the Humanitarian Device Exemption. To date, no subjects have been enrolled. The Institutional Review Board is currently reviewing its policies in light of the aforementioned scholarship.

The study can be found at the Health Affairs website: http://content.healthaffairs.org/content/30/2/302.abstract.

Weill Cornell Medical College

Weill Cornell Medical College, Cornell University’s medical school located in New York City, is committed to excellence in research, teaching, patient care and the advancement of the art and science of medicine, locally, nationally and globally. Physicians and scientists of Weill Cornell Medical College are engaged in cutting-edge research from bench to bedside, aimed at unlocking mysteries of the human body in health and sickness and toward developing new treatments and prevention strategies. In its commitment to global health and education, Weill Cornell has a strong presence in places such as Qatar, Tanzania, Haiti, Brazil, Austria and Turkey. Through the historic Weill Cornell Medical College in Qatar, the Medical College is the first in the U.S. to offer its M.D. degree overseas. Weill Cornell is the birthplace of many medical advances — including the development of the Pap test for cervical cancer, the synthesis of penicillin, the first successful embryo-biopsy pregnancy and birth in the U.S., the first clinical trial of gene therapy for Parkinson’s disease, and most recently, the world’s first successful use of deep brain stimulation to treat a minimally conscious brain-injured patient. Weill Cornell Medical College is affiliated with NewYork-Presbyterian Hospital, where its faculty provides comprehensive patient care at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. The Medical College is also affiliated with the Methodist Hospital in Houston, making Weill Cornell one of only two medical colleges in the country affiliated with two U.S.News & World Report Honor Roll hospitals. For more information, visit weill.cornell.edu.

 

Contact Info

Share on:
or:

MORE FROM Mental Health and Behavior

Health news